about-me variable
Clinilabs invites you to their event

Alzheimer’s Disease: Drug Development and the Changing Alzheimer’s Disease Therapeutic Landscape

About this event

Join us on Thursday, September 22, at 1 pm ET. Dr. Jeffrey Cummings will discuss drug development and the changing Alzheimer's Disease therapeutic landscape. Dr. Cummings will review in great length the following key items:

  • Candidate treatments in the drug development pipeline are directed at a wide variety of targets
  • Biomarkers play multiple key roles in Alzheimer’s Disease drug development
  • Anti-amyloid monoclonal antibodies are making progress toward approval and possible clinical implementation

Hosted by

  • Team member
    T
    Shannon Woodruf Marketing Manager @ Clinilabs Drug Development Corporation

    Shannon has more than 8 years of experience in the pharmaceutical industry. One of her passions is using her creativity and ingenuity to educate colleagues and the public about the benefits of clinical research.

  • Guest speaker
    JC G
    Jeffrey Cummings

Clinilabs

The CRO for CNS

We are a global, full-service contract research organization (CRO), the only one focused exclusively on central nervous system (CNS) drug development. We are dedicated to bringing new therapies to patients living with mental health, neurological and substance abuse disorders.